- Wheeler Bio has appointed Patrick Lucy as its new CEO, bringing over 32 years of biotechnology experience to the role.
- Lucy’s appointment comes as the company transitions towards fully integrated, commercial-scale contract development and manufacturing (CDMO) operations.
Wheeler Bio has announced the appointment of Patrick Lucy as its new Chief Executive Officer, signalling a key leadership shift as the company moves towards expanding its contract development and manufacturing (CDMO) capabilities. With more than 32 years of experience in the biotechnology sector, Lucy brings a wealth of knowledge in company scaling and operational growth to his new role.
Lucy most recently served as President and CEO of RoslinCT US, where he led the launch of Lykan Bioscience and later oversaw its sale to GHO Capital. His leadership in integrating Lykan and RoslinCT under a single brand helped establish the company as a prominent player in the cell therapy manufacturing space. He previously held senior positions at Pfenex Inc., which was acquired by Ligand Pharmaceuticals in 2020.
“We are thrilled to welcome Patrick to the Wheeler team,” said Jesse McCool, Co-Founder and Chief Scientific Officer of Wheeler Bio. “His track record in scaling biotechnology companies will guide Wheeler as we transition to a fully integrated commercial-scale CDMO.”
Wheeler Bio, based in Oklahoma, aims to position itself as a key player in the U.S. biotechnology ecosystem, supporting clinical and commercial-stage biotechnology production. Lucy’s appointment comes at a pivotal time for the company as it continues to build upon its scientific foundation and expand its market reach.
“I am honoured to join Wheeler Bio during this important phase of growth,” said Lucy. “I look forward to leading the company and strengthening Oklahoma’s presence in the biotechnology industry.”
Overview of outsourcing trends 
